Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton
The response of active and quiescent Crohn’s disease to prednisone,
sulfasalazine, or azathioprine has been studied in 569 patients in a
placebo-controlled, randomized, multicenter cooperative trial. The response of
active symptomatic disease to prednisone or sulfasalazine was significantly
better than to placebo. Response to azathioprine was better than to placebo, but
the difference did not reach conventional levels of statistical significance.
Patients with colonic involvement were especially responsive to sulfasalazine,
and those with small bowel involvement were especially responsive to prednisone.
Patients’ drug therapy immediately before entry to the study significantly
affected subsequent response. For patients with quiescent disease, none of the
drugs was superior to placebo in prophylaxis against flare-up or recurrence.
There is less than a 5% risk that a clinically significant prophylactic effect of
any of the drug regimens was missed.